Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

FBLG

FibroBiologics Inc

May 01 • 04:00PM ET

7.93

Dollar change -1.50
Percentage change -15.91	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: TXSS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	18.87%	Shs Outstand	28.23M	Perf Week	-31.16%
Market Cap	259.47M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	26.55M	Perf Month	-26.57%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.00%	Short Float	0.02%	Perf Quarter	-72.75%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.05	Perf Half Y	-
Book/sh	0.04	P/B	178.68	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf Year	-
Cash/sh	0.28	P/C	28.33	EPS next 5Y	-	ROE	-	52W Range	6.53 - 55.00	Perf YTD	-72.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-85.58%	Beta	-
Dividend TTM	-	Quick Ratio	1.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.44%	ATR (14)	1.39
Dividend Ex-Date	-	Current Ratio	1.00	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	34.90	Volatility	13.23% 10.80%
Employees	10	Debt/Eq	1.40	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	1.11	EPS Q/Q	-	Payout	-	Rel Volume	0.63	Prev Close	9.43
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	93.47K	Price	7.93
SMA20	-26.79%	SMA50	-29.07%	SMA200	-31.72%	Trades		Volume	61,377	Change	-15.91%

Apr-25-24 08:00AM	FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids (GlobeNewswire)
Apr-11-24 09:31AM	FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office (GlobeNewswire)
Apr-04-24 09:31AM	FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA (GlobeNewswire)
Mar-28-24 09:31AM	FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus (GlobeNewswire) -8.00%
Mar-19-24 09:31AM	FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment (PR Newswire) +21.36%
09:31AM	Loading…
Mar-13-24 09:31AM	FibroBiologics to Present at Advanced Wound Care Summit USA (PR Newswire) -5.83%
Mar-06-24 09:31AM	FibroBiologics Appoints Ruben A. Garcia as General Counsel (PR Newswire)
Feb-29-24 05:44PM	FibroBiologics Files 2023 Form 10-K Annual Report (PR Newswire)
Feb-20-24 09:31AM	FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum (PR Newswire) -8.52%
Feb-13-24 09:31AM	FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases (PR Newswire) +88.38%
Feb-08-24 09:31AM	FibroBiologics Announces Three United States Patents for Fibroblast Technology (PR Newswire) -9.91%
Feb-06-24 09:31AM	FibroBiologics Announces Three Japanese Patents on Fibroblast Technology (PR Newswire) -28.26%
Jan-31-24 10:00AM	FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG (PR Newswire)

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm's product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O'Heeron on April 8, 2021 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBLG

FibroBiologics Inc

Upgrade your FINVIZ experience